FLT3 and acute myeloid leukemia: Since 2017, the standard of care for fit patients with ND FLT-3 m AML has been 7 + 3 chemotherapy with the addition of Midostaurin, based on the results of the Phase III RATIFY trial, which showed prolonged survival when Midostaurin was added to intensive chemotherapy [21].